摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-溴-2-疏基苯并噻唑 | 1083181-41-2

中文名称
4-溴-2-疏基苯并噻唑
中文别名
4-溴-2-巯基苯并噻唑
英文名称
4-bromo-2-mercaptobenzothiazole
英文别名
4-bromo-3H-1,3-benzothiazole-2-thione
4-溴-2-疏基苯并噻唑化学式
CAS
1083181-41-2
化学式
C7H4BrNS2
mdl
MFCD11044824
分子量
246.151
InChiKey
CNIJVNGILLYJHJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    184-185 °C
  • 沸点:
    350.6±44.0 °C(Predicted)
  • 密度:
    1.93±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    69.4
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2934200090

SDS

SDS:854a2517980f3165d9377bfae4fa6802
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-Bromo-2-mercaptobenzothiazole
Synonyms: 4-Bromobenzo[d]thiazole-2-thiol

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromo-2-mercaptobenzothiazole
CAS number: 1083181-41-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H4BrNS2
Molecular weight: 246.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-溴-2-疏基苯并噻唑potassium permanganate四(三苯基膦)钯potassium carbonate三乙胺 作用下, 以 1,4-二氧六环二氯甲烷溶剂黄146 为溶剂, 反应 6.75h, 生成 2-methylsulfonyl-4-phenyl-1,3-benzothiazole
    参考文献:
    名称:
    Optimization of Benzothiazole and Thiazole Hydrazones as Inhibitors of Schistosome BCL-2
    摘要:
    DOI:
    10.1021/acsinfecdis.0c00700
  • 作为产物:
    参考文献:
    名称:
    [EN] COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY
    [FR] COMPOSÉS POUR LA MODULATION DE L'ACTIVITÉ DE MYC
    摘要:
    本发明提供了式(I)和式(II)的新化合物以及药学上可接受的盐、溶剂合物、水合物、互变异构体、立体异构体、同位素标记衍生物及其组合物。还提供了涉及这些化合物或组合物用于治疗或预防增生性疾病的方法和试剂盒,例如癌症(如乳腺癌、前列腺癌、淋巴瘤、肺癌、胰腺癌、卵巢癌、神经母细胞瘤或结肠直肠癌)、良性肿瘤、血管生成、炎症性疾病、纤维化(如多囊肾病)、自身炎症性疾病和自身免疫疾病的方法。
    公开号:
    WO2016197078A1
点击查看最新优质反应信息

文献信息

  • 2-AMINOPYRIDINE KINASE INHIBITORS
    申请人:Steinig Arno G.
    公开号:US20090197862A1
    公开(公告)日:2009-08-06
    2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, Flt3, FGFR3, Ab1, Aurora A, c-Src, IGF-1R, ALK, c-MET, RON, PAK1, PAK2, and TAK1, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention is further directed to a method of treating a patient having a condition which is mediated by protein kinase activity by administering to the patient a therapeutically effective amount of the above-mentioned pharmaceutical composition.
    具有Formula I结构的2-氨基吡啶化合物,以及这些化合物的药用可接受的盐。Formula I的化合物抑制动物(包括人类)中的酪氨酸激酶酶活性,并可用于治疗和/或预防各种疾病和病况。特别地,本文披露的化合物是激酶抑制剂,特别是但不限于KDR、Tie-2、Flt3、FGFR3、Ab1、Aurora A、c-Src、IGF-1R、ALK、c-MET、RON、PAK1、PAK2和TAK1,并可用于治疗增生性疾病,如但不限于癌症。本发明还涉及一种包含Formula I化合物的药物组合物,或其药用可接受的盐,以及药用可接受的载体的药物组合物。本发明还涉及一种通过向患有由蛋白激酶活性介导的病症的患者投与上述药物组合物的治疗方法。
  • A Convenient Metal-Free Method for the Synthesis of Benzothiazolethiones from o-Haloanilines and Carbon Disulfide
    作者:Chanjuan Xi、Peng Zhao、Fei Wang
    DOI:10.1055/s-0031-1289713
    日期:2012.5
    A convenient method has been developed for the preparation of a variety of 1,3-benzothiazole-2(3H)-thiones. The reaction proceeds from an o-haloaniline derivative and carbon disulfide in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene at 80-140 ˚C to give the corresponding 1,3-benzothiazole-2(3H)-thione derivatives in good-to-excellent yields. cyclizations - heterocycles - benzothiazoles - amines
    已经开发了一种方便的方法来制备各种1,3-苯并噻唑-2(3 H)-硫酮。反应是在80-140℃下,在1,8-二氮杂双环[5.4.0]十一碳-7-烯存在下,由邻卤代苯胺衍生物和二硫化碳进行的,得到相应的1,3-苯并噻唑-2(3 H)-硫酮衍生物,收率良好。 环化-杂环-苯并噻唑-胺-二硫化碳-串联反应
  • 2-aminopyridine kinase inhibitors
    申请人:OSI Pharmaceuticals, LLC
    公开号:US08178668B2
    公开(公告)日:2012-05-15
    2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, Flt3, FGFR3, Ab1, Aurora A, c-Src, IGF-1R, ALK, c-MET, RON, PAK1, PAK2, and TAK1, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention is further directed to a method of treating a patient having a condition which is mediated by protein kinase activity by administering to the patient a therapeutically effective amount of the above-mentioned pharmaceutical composition.
    具有I式结构的2-氨基吡啶化合物,以及这些化合物的药学上可接受的盐。I式化合物抑制动物(包括人类)中的酪氨酸激酶酶活性,并在治疗和/或预防各种疾病和病况方面有用。特别地,本文披露的化合物是激酶抑制剂,特别是但不限于KDR,Tie-2,Flt3,FGFR3,Ab1,Aurora A,c-Src,IGF-1R,ALK,c-MET,RON,PAK1,PAK2和TAK1,并可用于治疗增殖性疾病,例如但不限于癌症。本发明还涉及一种制备药物组合物的方法,该组合物包括I式化合物或其药学上可接受的盐的治疗有效量以及药学上可接受的载体。本发明还涉及一种通过向患有蛋白激酶活性介导的病症的患者投与上述药物组合物的治疗方法。
  • Selective Inhibition of Extracellular Thioredoxin by Asymmetric Disulfides
    作者:Thomas R. DiRaimondo、Nicholas M. Plugis、Xi Jin、Chaitan Khosla
    DOI:10.1021/jm301775s
    日期:2013.2.14
    Whereas the role of mammalian thioredoxin (Trx) as an intracellular protein cofactor is widely appreciated, its function in the extracellular environment is not well-understood. Only few extracellular targets of Trx-mediated thiol disulfide exchange are known. For example, Trx activates extracellular transglutaminase 2 (TG2) via reduction of an intramolecular disulfide bond. Because hyperactive TG2 is thought to play a role in various diseases, understanding the biological role of utracellular Trx may provide critical insight into the pathogenesis of these disorders. Starting from a clinical-stage asymmetric disulfide lead, we have identified analogs with >100-fold specificity for Trx. Structure-activity relationship and computational docking model analyses have provided insights into the features important for enhancing potency and specificity. The most active compound identified had an IC50 below 0.1 mu M in cell culture and may be appropriate for in vivo use to interrogate the role of extracellular Trx in health and disease.
  • Synthesis of 2-Mercaptobenzothiazoles via DBU-Promoted Tandem Reaction of <i>o</i>-Haloanilines and Carbon Disulfide
    作者:Fei Wang、Shangjun Cai、Zhipeng Wang、Chanjuan Xi
    DOI:10.1021/ol2011105
    日期:2011.6.17
    An efficient strategy for the synthesis of a variety of 2-mercaptobenzothiazole derivatives has been developed. The reaction proceeded from o-haloaniline derivatives and carbon disulfide via a tandem reaction in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) to afford the corresponding 2-mercaptobenzothiazole derivatives in good to excellent yields.
查看更多

同类化合物

(1Z)-1-(3-乙基-5-羟基-2(3H)-苯并噻唑基)-2-丙酮 齐拉西酮砜 阳离子蓝NBLH 阳离子荧光黄4GL 锂2-(4-氨基苯基)-5-甲基-1,3-苯并噻唑-7-磺酸酯 铜酸盐(4-),[2-[2-[[2-[3-[[4-氯-6-[乙基[4-[[2-(硫代氧代)乙基]磺酰]苯基]氨基]-1,3,5-三嗪-2-基]氨基]-2-(羟基-kO)-5-硫代苯基]二氮烯基-kN2]苯基甲基]二氮烯基-kN1]-4-硫代苯酸根(6-)-kO]-,(1:4)氢,(SP-4-3)- 铜羟基氟化物 钾2-(4-氨基苯基)-5-甲基-1,3-苯并噻唑-7-磺酸酯 钠3-(2-{(Z)-[3-(3-磺酸丙基)-1,3-苯并噻唑-2(3H)-亚基]甲基}[1]苯并噻吩并[2,3-d][1,3]噻唑-3-鎓-3-基)-1-丙烷磺酸酯 邻氯苯骈噻唑酮 西贝奈迪 螺[3H-1,3-苯并噻唑-2,1'-环戊烷] 螺[3H-1,3-苯并噻唑-2,1'-环己烷] 葡萄属英A 草酸;N-[1-[4-(2-苯基乙基)哌嗪-1-基]丙-2-基]-2-丙-2-基氧基-1,3-苯并噻唑-6-胺 苯酰胺,N-2-苯并噻唑基-4-(苯基甲氧基)- 苯酚,3-[[2-(三苯代甲基)-2H-四唑-5-基]甲基]- 苯胺,N-(3-苯基-2(3H)-苯并噻唑亚基)- 苯碳杂氧杂脒,N-1,2-苯并异噻唑-3-基- 苯甲基2-甲基哌啶-1,2-二羧酸酯 苯并噻唑正离子,2-[3-(1,3-二氢-1,3,3-三甲基-2H-吲哚-2-亚基)-1-丙烯-1-基]-3-乙基-,碘化(1:1) 苯并噻唑正离子,2-[(2-乙氧基-2-羰基乙基)硫代]-3-甲基-,溴化 苯并噻唑啉 苯并噻唑-d4 苯并噻唑-6-腈 苯并噻唑-5-羧酸 苯并噻唑-5-硼酸频哪醇酯 苯并噻唑-4-醛 苯并噻唑-4-乙酸 苯并噻唑-2-磺酸钠 苯并噻唑-2-磺酸 苯并噻唑-2-磺酰氟 苯并噻唑-2-甲醛 苯并噻唑-2-甲酸 苯并噻唑-2-甲基甲胺 苯并噻唑-2-基磺酰氯 苯并噻唑-2-基叠氮化物 苯并噻唑-2-基-邻甲苯-胺 苯并噻唑-2-基-己基-胺 苯并噻唑-2-基-(4-氯-苯基)-胺 苯并噻唑-2-基-(4-氟-苯基)-胺 苯并噻唑-2-基-(4-乙氧基-苯基)-胺 苯并噻唑-2-基-(2-甲氧基-苯基)-胺 苯并噻唑-2-基-(2,6-二甲基-苯基)-胺 苯并噻唑-2-基(对甲苯基)甲醇 苯并噻唑-2-乙酸甲酯 苯并噻唑-2-乙腈 苯并噻唑-2(3H)-酮N2-[1-(吡啶-4-基)乙亚基]腙 苯并噻唑-2 - 丙基 苯并噻唑,6-(3-乙基-2-三氮烯基)-2-甲基-(8CI)